Somatostatin-derived analogues play an important role in the diagnosis and treatment of neuroendocrine tumors. The aim of this study was to evaluate a new somatostatin analogue designed for labeling with 99mTc: [6-hydrazinopyridine-3-carboxylic acid (HYNIC0), β-(3-benzothienyl)-Ala (BzThi3)]-octreotide ([HYNIC]-BOC), using ethylenediamine-N,N′-diacetic acid (EDDA) and tricine as coligands. Synthesis was performed on a solid phase using a standard Fmoc strategy. The HYNIC-peptide conjugate was radiolabeled with 99mTc and characterized by ITLC and high-performance liquid chromatography (HPLC). In vitro studies were carried out in sstr2 expressing AR4-2J cell lines. In vivo distribution studies were performed in rats bearing the AR4-2J tumor. The radiolabeled complex could be prepared at high-specific activities and >95% radiochemical yield as determined by HPLC. The peptide conjugate showed high-affinity binding for sstr2. The radioligand showed high and specific internalization into AR4-2J cells (18.19%±0.21% at 4 hours). In vivo distribution studies in rats bearing tumor have shown a receptor-specific uptake of radioactivity in somatostatin receptor-positive organs. After 4 hours, uptake in the AR4-2J tumor was 1.71%±0.36% injected dose per gram tissue (%ID/g). These data show that [99mTc/EDDA/Tricine/HYNIC0, BzThi3]-octreotide is a specific radioligand for the somatostatin receptor-positive tumors and is a suitable candidate for clinical studies.
Get full access to this article
View all access options for this article.
References
1.
ReubiJC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 2003; 24:389.
2.
WeinerRE, ThakurML. Radiolabeled peptides in oncology: Role in diagnosis and treatment. Bio Drugs, 2005; 19:145.
3.
ReubiJC, MaeckeHR, KrenningEP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med, 2005; 46:67S.
4.
HeppelerA, FroidevauxS, EberleANet al.Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem, 2000; 7:971.
5.
BoermanOC, OyenWJ, CorstensFH. Radiolabeled receptor-binding peptides: A new class of radiopharmaceuticals. Semin Nucl Med, 2000; 30:195.
6.
KrenningEP, KwekkeboomDJ, BakkerWHet al.Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I- Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med, 1993; 20:716.
HenzeM, SchuhmacherJ, HippPet al.PET imaging of somatostatin receptors using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. J Nucl Med, 2001; 42:1053.
9.
AndersonCJ, JonesAL, BassLAet al.Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med, 1998; 39:1944.
10.
SpragueJE, PengY, SunXet al.Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res, 2004; 10:8674.
11.
KwekkeboomDJ, BakkerWH, KamBLet al.Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging, 2003; 30:417.
FaintuchBL, PereiraNPS, FaintuchSet al.Direct labeling studies of octapeptides with rhenium-188. Radiochimica Acta, 2003; 91:427.
15.
GandomkarM, NajafiR, Sadat EbrahimiSEet al.Direct labelling of octreotide with 99mTc: Effect of different concentration of reducing agents and amount of sodium pertechnetate on radiolabelling efficiency. Appl Radiat Isot, 2003; 58:361.
16.
MainaT, StolzB, AlbertRet al.Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219–387) labelled with technetium-99m. Eur J Nucl Med, 1994; 21:437.
17.
MainaT, NockB, NikolopoulouAet al.[99mTc] Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumors: Synthesis and preclinical results. Eur J Nucl Med Mol Imaging, 2002; 29:742.
18.
LiuS, EdwardsDS, LoobyRJet al.Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: Effects of chelators on properties of [99mTc]chelator-peptide conjugates. Bioconjug Chem, 1996; 7:196.
19.
DecristoforoC, Melendez-AlafortL, SosabowskiJKet al.99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med, 2000; 41:1114.
20.
SpradauTW, EdwardsWB, AndersonCJet al.Synthesis and Biological Evaluation of Tc-99m-Cyclopentadienyltricarbonyltechnetium-Labeled octreotide. Nucl Med Biol, 1999; 26:1.
21.
AbramsMJ, JuweidM, tenKateCIet al.Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med, 1990; 31:2022.
22.
GandomkarM, NajafiR, EbrahimiFet al.Clinical evaluation of antimicrobial peptide [99mTc/Tricine/HYNIC0] ubiquicidin 29–41 as a human-specific infection imaging agent. Nucl Med Biol, 2009; 36:199.
23.
BabichJW, FischmanAJ. Effect of “co-ligand” on the biodistribution of 99mTc labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl Med Biol, 1995; 22:25.
24.
ReubiJC, WaserB, SchaerJCet al.Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med, 2001; 28:836.
25.
ReubiJC, ScharJC, WaserBet al.Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med, 2000; 27:273.
26.
FeroneD, van HagenMP, KwekkeboomDJet al.Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab, 2000; 85:1719.
27.
PapottiM, CroceS, BelloMet al.Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumors. Correlation with preoperative octreotide scintigraphy. Virchows Arch, 2001; 439:787.
28.
ReubiJC, WaserB. Concomitant expression of several peptide receptors in neuroendocrine tumors: Molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging, 2003; 30:781.
29.
Forssell-AronssonEB, NilssonO, BenjegardSAet al.111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med, 2000; 41:636.
WildD, SchmittJS, GinjMet al.DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging, 2003; 30:1338.
32.
GinjM, ChenJ, WalterMAet al.Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res, 2005; 11:1136.
33.
GabrielM, DecristoforoC, DonnemillerEet al.An intrapatient comparison of 99mTc-EDDA/HYNICTOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med, 2003; 44:708.
34.
GandomkarM, NajafiaR, ShafieiMet al.Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors. Nucl Med Biol, 2007; 34:651.
VirgoliniI, BrittonK, BuscombeJet al.111In-and 90Y-DOTA-lanreotide: Results and implications of the Mauritius trial. Semin Nucl Med, 2002; 32:148.
37.
De JongM, BreemanWAP, BakkerWHet al.Comparision of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res, 1998; 58:437.
38.
StorchD, BeheM, WalterMAet al.Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization?J Nucl Med, 2005; 46:1561.
39.
RaulfF, PerezJ, JoyerDet al.Differential expression of five somatostatin receptor subtypes, sstr1–5, in the CNS and peripheral tissue. Digestion, 1994; 55:46.
